Furoscix ReadyFlow demonstrated a bioavailability of 107.3% relative to IV furosemide, with comparable diuresis, natriuresis, and kaliuresis at 6, 8, and 12 hours postdose. The Food and Drug ...
New findings explore the adalimumab biosimilar landscape, focusing on formulation, devices, and patient support programs that enhance treatment experiences. Not all adalimumab biosimilars are created ...
The price you pay for Humira (adalimumab) may depend on factors such as the form you take, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help ...
Celltrion USA launched its fifth biosimilar in the United States, Yuflyma (adalimumab-aaty), a biosimilar referencing Humira that is also 1 of 8 adalimumab products expected to launch in July.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results